Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients

Biological Chemistry

Volumn 383, Issue 7-8, 2002, Pages 1297-1303

  Scorilas, Andreas ^a   Fotiou, Stelios ^a   Tsiambas, Evangelos ^a   Yotis, Julia ^a   Kotsiandri, Fani ^a   Sameni, Mansoureh ^a   Sloane, Bonnie F ^a   Talieri, Maroulio ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Cathepsin B; Immunohistochemistry; Ovarian cancer

Indexed keywords

CATHEPSIN B; PARAFFIN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; ADULT; AGED; DISEASE COURSE; ENZYMOLOGY; MIDDLE AGED; MORTALITY; OVARY TUMOR; RECURRENT DISEASE; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN B; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, PROGESTERONE; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0036660666     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.146     Document Type: Article

References (27)

1. Berquin, I. M., and Sloane, B.F. (1996). Cathepsin B expression in human tumors. In: Intracellular Protein Metabolism, K. Suzuki and J. Bond, eds. (New York, USA: Plenum Press), pp. 281-294.
2. Campo, E., Munoz, J., Miquel, R., Palacin, A., Cardesa, A., Sloane, B.F., and Emmert-Buck, M.R. (1994). Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145, 301-309.
3. Demchik, L.L., Sameni, M., Nelson, K., Mikkelsen, T., and Sloane, B.F. (1999). Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 17, 483-494.
4. Fernandez, P.L., Farre, X., Nadal, A., Fernandez, E., Peiro, N., Sloane, B.F., Shi, G.R., Chapman, H.A., Campo, E., Cardesa, A. (2001). Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 95, 51-55.
5. Haczynska, H., Gerber, J., Warwas, M., and Andrzejeewski L. (1998). Dependence of serous activity of cathepsin B on histological types of ovarian carcinomas. Ginekol. Pol. 69, 191-195.
6. Harbeck, N., Alt, U., Berger, U., Kruger, A., Thomssen, C., Janicke, F., Ho, H., Kates, R.E., and Schmitt, M. (2001). Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsin B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin. Cancer Res. 7, 2757-2764.
7. Kaplan, E.L., and Meier P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
8. Karameris, A., Panagou, R., Tsilalis, T., and Bouros, D. (1997). Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am. J. Respir. Crit. Care Med. 156, 1930-1936.
9. Kobayashi, H., Mobuhiko, N., Sugimura, M., Shinohara, H., Ohi, H. and Terao T. (1993a). Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer 84, 633-640.
10. Kobayashi, H., Mobuhiko, N., Sugimura, M., Shinohara, H., Ohi, H., and Terao, T. (1993b). Effect of membrane-associated cathepsin B on the activation of receptor-bound pro-urokinase and subsequent invasion of reconstituted basement membranes. Biochim. Biophys. Acta 1178, 55-62.
11. Kos, J., and Lah, T.T. (1998). Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5, 1349-1361.
12. Lah, T., and Kos, J. (1998). Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379, 125-130.
13. Lambet-Messerlian, G.M. (2000). Is inhibin a serum marker for ovarian cancer? Eur. J. Endocrinol. 42, 331-333.
14. Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Piccinno, R., Rigault de la Longrais, I.A., Howarth, D.J., and Diamandis, E.R. (2001). Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res. 7, 2372 -2379.
15. Maggino, T., and Gadducci, A. (2000). Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur. J. Gynaecol. Oncol. 21, 64-69.
16. Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Danese, S., and Diamandis, E.P. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 7, 806- 811.
17. McKerrow, J., Bhargava, V., Hansell, E., Huling, S., Kuwahara, T., Matley, M., Coussens, L., and Warren, R. (2000). A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. 6, 450-460.
18. Menon, U., and Jacobs, I.J. (2000). Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 12, 39-42.
19. Obiezu, C.V., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Rigault de la Longrais, I.A., Arisio, R., and Diamandis, E.P. (2001). Higher human kallikrein gene 4 (KLK4) expression indicated poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7, 2380-2386.
20. Papadopoulou, S., Scorilas, A., Arnogianaki N., Papapanayiotou, B., Tzimogiani, A., Agnantis N., and Talieri M. (2001). Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumor Biol. 22, 383-389.
21. Riman, T., Persson, L., and Staffin, N. (1998). Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin. Endocrinol. 49, 695-707.
22. Schmalfeldt, B., Prechtel, D., Harting, K., Spathe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W., and Lengyel, E. (2001). Increased expression of matrix mettalloproteinases (MMP-2 and MMP-9), and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7, 2396-2404.
23. Scorilas, A., Karameris, A., Arnogiannaki, N., Ardavanis, A., Bassilopoulos, R., Trangas, T., Talieri, M. (2001). Overexpression of metalloproteinase-9 in human breast cancer: a potential favorable indicator in node-negative patients. Br. J. Cancer 84, 1488-1496.
24. Yan, S., Sameni M., and Sloane, B. (1998). Cathepsin B and human tumor progression. Biol. Chem. 379, 113 -123.
25. Yousef, G.M., Kyriakopoulou, L.G., Scorilas, A., Fracchioli, S., Ghiringhe, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W., Richiardi, G., Massobrio, M., Diamandis, E.R., and Katsaros, D. (2001). Quantitative expression of human kallikrein gene 9 (KLK9) in ovarian cancer: an independent and favorable prognostic marker. Cancer Res. 61, 7811-7818.
26. Warwas, M., Gerber, J., Haczynska, H., and Lukasik-Lemanska, K. (2000). Comparison of cathepsin-B-like activity and CA 125 assays use in ovarian cancer diagnosis. Ginekol. Pol. 71, 400-405.
27. Werle, B., Kraft, A., Lah, T., Kos, J., Schanzenbacher, U., Krayser, K., and Ebert, W. (2000). Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non-small cell lung carcinoma. Cancer 89, 2282-2291.